Stonebridge Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $330K | Sell |
1,517
-76
| -5% | -$16.9K | 0.02% | 171 |
|
|
2025
Q4 | $364K | Sell |
1,593
-333
| -17% | -$75.9K | 0.03% | 156 |
|
|
2025
Q3 | $446K | Buy |
1,926
+26
| +1% | +$5.29K | 0.03% | 144 |
|
|
2025
Q2 | $353K | Sell |
1,900
-163
| -8% | -$30.3K | 0.03% | 154 |
|
|
2025
Q1 | $432K | Buy |
2,063
+349
| +20% | +$67.8K | 0.04% | 139 |
|
|
2024
Q4 | $305K | Sell |
1,714
-8
| -0.5% | -$1.47K | 0.02% | 170 |
|
|
2024
Q3 | $340K | Sell |
1,722
-101
| -6% | -$18.9K | 0.03% | 169 |
|
|
2024
Q2 | $313K | Sell |
1,823
-286
| -14% | -$47.4K | 0.03% | 166 |
|
|
2024
Q1 | $384K | Buy |
2,109
+214
| +11% | +$36.9K | 0.03% | 161 |
|
|
2023
Q4 | $294K | Buy |
1,895
+4
| +0.2% | +$583 | 0.03% | 167 |
|
|
2023
Q3 | $282K | Sell |
1,891
-159
| -8% | -$23.3K | 0.03% | 166 |
|
|
2023
Q2 | $276K | Sell |
2,050
-244
| -11% | -$35.8K | 0.03% | 171 |
|
|
2023
Q1 | $366K | Sell |
2,294
-59,526
| -96% | -$9.1M | 0.04% | 146 |
|
|
2022
Q4 | $9.99M | Buy |
61,820
+1,573
| +3% | +$241K | 1.18% | 31 |
|
|
2022
Q3 | $8.09M | Buy |
60,247
+600
| +1% | +$86.1K | 1.04% | 37 |
|
|
2022
Q2 | $9.14M | Sell |
59,647
-50,108
| -46% | -$7.66M | 1.11% | 35 |
|
|
2022
Q1 | $17.8M | Sell |
109,755
-1,935
| -2% | -$281K | 1.92% | 6 |
|
|
2021
Q4 | $15.1M | Buy |
111,690
+4,047
| +4% | +$478K | 1.67% | 10 |
|
|
2021
Q3 | $11.6M | Sell |
107,643
-100,989
| -48% | -$11.5M | 1.41% | 16 |
|
|
2021
Q2 | $23M | Buy |
208,632
+106,532
| +104% | +$12M | 1.46% | 17 |
|
|
2021
Q1 | $11M | Buy |
102,100
+2,188
| +2% | +$234K | 1.46% | 16 |
|
|
2020
Q4 | $10.7M | Sell |
99,912
-432
| -0.4% | -$41.5K | 1.62% | 15 |
|
|
2020
Q3 | $8.79M | Sell |
100,344
-825
| -0.8% | -$77.7K | 1.58% | 19 |
|
|
2020
Q2 | $9.93M | Sell |
101,169
-1,557
| -2% | -$137K | 1.84% | 8 |
|
|
2020
Q1 | $7.83M | Buy |
102,726
+1,207
| +1% | +$103K | 1.65% | 11 |
|
|
2019
Q4 | $8.99M | Buy |
101,519
+2,850
| +3% | +$237K | 1.47% | 15 |
|
|
2019
Q3 | $7.47M | Buy |
98,669
+6,042
| +7% | +$414K | 1.29% | 26 |
|
|
2019
Q2 | $6.74M | Buy |
92,627
+2,319
| +3% | +$182K | 1.2% | 29 |
|
|
2019
Q1 | $7.28M | Buy |
90,308
+5,201
| +6% | +$425K | 1.35% | 23 |
|
|
2018
Q4 | $7.85M | Buy |
85,107
+3,636
| +4% | +$320K | 1.83% | 11 |
|
|
2018
Q3 | $7.71M | Sell |
81,471
-359
| -0.4% | -$34K | 1.55% | 18 |
|
|
2018
Q2 | $7.58M | Buy |
81,830
+2,276
| +3% | +$222K | 1.65% | 16 |
|
|
2018
Q1 | $7.53M | Sell |
79,554
-7,289
| -8% | -$801K | 1.73% | 12 |
|
|
2017
Q4 | $8.4M | Sell |
86,843
-24,142
| -22% | -$2.28M | 1.92% | 9 |
|
|
2017
Q3 | $9.86M | Sell |
110,985
-1,625
| -1% | -$124K | 2.42% | 4 |
|
|
2017
Q2 | $8.16M | Buy |
112,610
+1,375
| +1% | +$92.4K | 2.14% | 5 |
|
|
2017
Q1 | $7.25M | Buy |
111,235
+3,109
| +3% | +$195K | 1.97% | 6 |
|
|
2016
Q4 | $6.77M | Buy |
108,126
+280
| +0.3% | +$17.1K | 2.01% | 6 |
|
|
2016
Q3 | $6.8M | Buy |
107,846
+3,973
| +4% | +$257K | 2.13% | 5 |
|
|
2016
Q2 | $6.43M | Buy |
103,873
+2,736
| +3% | +$167K | 2.18% | 5 |
|
|
2016
Q1 | $5.78M | Buy |
101,137
+964
| +1% | +$53.7K | 2.04% | 13 |
|
|
2015
Q4 | $5.93M | Buy |
100,173
+2,741
| +3% | +$158K | 2.17% | 10 |
|
|
2015
Q3 | $5.3M | Buy |
97,432
+34,925
| +56% | +$2.27M | 2.13% | 8 |
|
|
2015
Q2 | $4.2M | Buy |
62,507
+4,390
| +8% | +$287K | 1.61% | 15 |
|
|
2015
Q1 | $3.4M | Buy |
58,117
+19,292
| +50% | +$1.17M | 1.31% | 21 |
|
|
2014
Q4 | $2.54M | Buy |
38,825
+3,758
| +11% | +$237K | 1.04% | 37 |
|
|
2014
Q3 | $2.02M | Buy |
35,067
+5,392
| +18% | +$299K | 0.89% | 42 |
|
|
2014
Q2 | $1.68M | Buy |
29,675
+3,106
| +12% | +$163K | 0.76% | 53 |
|
|
2014
Q1 | $1.37M | Buy |
26,569
+6,623
| +33% | +$335K | 0.67% | 58 |
|
|
2013
Q4 | $1.05M | Buy |
+19,946
| New | +$980K | 0.54% | 67 |
|
Other funds holding ABBV
VCM
VPM
Stonebridge Capital Advisors's ABBV Position: Q1 2026 in Review
Stonebridge Capital Advisors reduced its AbbVie (ABBV) stake by 4.8% in Q1 2026, selling an estimated $16.9K and leaving 1,517 shares worth $330K. The position accounts for 0.02% of the portfolio, ranked #171.
Stonebridge Capital Advisors first reported a position in ABBV in Q4 2013 and has held it in 50 quarters since. The position peaked at $23M in Q2 2021. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Stonebridge Capital Advisors held 1,517 shares of AbbVie worth $330K as of Q1 2026.
- Stonebridge Capital Advisors sold 76 AbbVie shares in Q1 2026, an estimated $16.9K.
- AbbVie made up 0.02% of Stonebridge Capital Advisors's portfolio in Q1 2026, its #171 holding.
- Stonebridge Capital Advisors first reported a position in AbbVie in Q4 2013 and has held it in 50 quarters since.
- Stonebridge Capital Advisors's AbbVie position peaked at $23M in Q2 2021.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Stonebridge Capital Advisors's 13F filing for Q1 2026, filed 14 May 2026.